Fibrinolytic and Antifibrinolytic Drugs: 2026 Stroke Treatment, Tranexamic Acid and Safety

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment.

Clinical overview

Fibrinolytics accelerate breakdown of fibrin-rich thrombi, whereas antifibrinolytics inhibit plasmin-mediated fibrin dissolution. Their indications are distinct and time-sensitive. The major hazard of fibrinolysis is intracranial or systemic bleeding; antifibrinolytics require selection based on bleeding etiology and thrombosis risk [1, 2, 3].

Classification and mechanisms

  • Recombinant tissue plasminogen activators: alteplase, tenecteplase and reteplase enhance conversion of plasminogen into plasmin; tenecteplase has longer half-life and greater fibrin specificity than alteplase.
  • Streptokinase and urokinase: historical/region-specific plasminogen activators; streptokinase is antigenic and can cause allergic reactions.
  • Tranexamic acid (TXA) and aminocaproic acid: lysine analogues that inhibit plasminogen binding to fibrin and reduce fibrin degradation.
  • Aprotinin: serine protease inhibitor used in selected cardiac surgery settings where authorized; it is an antifibrinolytic, not a fibrinolytic [1].

Acute ischemic stroke — 2026 AHA/ASA

For carefully selected adults with disabling acute ischemic stroke within 4.5 hours of onset or last known well, the 2026 AHA/ASA guideline endorses either IV tenecteplase 0.25 mg/kg (maximum 25 mg) or alteplase 0.9 mg/kg (maximum 90 mg). These are stroke-specific doses, not interchangeable with myocardial infarction dosing. Advanced imaging may support thrombolysis in selected unknown-onset or 4.5–9-hour cases. Non-disabling stroke generally should not receive IV thrombolysis. Neuroimaging must exclude intracranial hemorrhage and eligibility assessment is essential [2].

Other thrombolysis indications

Systemic fibrinolysis may be appropriate for selected massive/high-risk pulmonary embolism with hemodynamic compromise, and for STEMI when timely primary PCI is unavailable and criteria are met; dosing, timing and contraindications differ by indication. In many acute MI settings, primary PCI is preferred when feasible. Catheter-directed regimens require specialist teams [1].

Tranexamic acid applications

TXA reduces bleeding in selected trauma, surgery, heavy menstrual bleeding and postpartum hemorrhage. In postpartum hemorrhage, WHO recommends prompt IV TXA within three hours of birth in addition to standard care, regardless of whether the cause is atony or genital tract trauma. TXA is not a uterotonic and does not replace source control, blood products, or surgery when needed [3].

Safety and contraindications

Before fibrinolysis, assess recent intracranial hemorrhage, active bleeding, uncontrolled severe hypertension, anticoagulants and other protocol-specific exclusions. Following therapy, monitor neurologic status and bleeding. TXA is mainly renally cleared, so adjust in renal dysfunction; high IV doses or improper intrathecal administration can cause seizures. Restrict TXA where active intravascular thrombosis or other labeled contraindications apply; monitor renal function and thrombotic risk [1, 2, 3].

Selecting patients with deep vein thrombosis

Anticoagulation alone is appropriate for most proximal deep vein thromboses. A limb-threatening presentation such as phlegmasia cerulea dolens warrants urgent specialist assessment for thrombus removal. Thrombolysis may also be considered in selected patients with symptomatic iliofemoral thrombosis and a low bleeding risk. A contraindication to anticoagulation is insufficient grounds for giving a fibrinolytic, which itself carries substantial bleeding risk. [4]

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. American Heart Association/American Stroke Association. 2026 guideline for the early management of patients with acute ischemic stroke. Stroke. 2026. doi:10.1161/STR.0000000000000513. Available from: https://doi.org/10.1161/STR.0000000000000513
  3. World Health Organization. WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. Geneva: WHO; 2017. Available from: https://www.who.int/publications/i/item/WHO-RHR-17.21
  4. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–4738. View source.
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *